Effects of tirofiban on haemostatic activation in vitro

British Journal of Anaesthesia

Volumn 93, Issue 2, 2004, Pages 263-269

  Tanaka, Kenichi A ^a   Katori, N ^a   Szlam, F ^a   Sato, N ^a   Kelly, A B ^a   Levy, A H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood, antithrombin; Blood, platelet inhibitors, tirofiban; Complications, heparin

Indexed keywords

ADENOSINE DIPHOSPHATE; HEPARIN; THROMBIN; TIROFIBAN;

ANALYZER; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DEVICE; DRUG MECHANISM; HEART SURGERY; HEMOSTASIS; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

EID: 4344622551     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeh193     Document Type: Article

References (30)

1. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997; 85: 498-506
2. Dietrich W, Braun S, Spannagl M, Richter JA. Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients. Anesth Analg 2001; 92: 66-71
3. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997; 96: 3534-41
4. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl J Med 1998; 338: 1488-97
5. Koster A, Meyer O, Fischer T, et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg 2001; 122: 1254-5
6. Koster A, Chew DP, Kuebler W, et al. Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass. Am J Cardiol 2003; 91: 346-7
7. Bizzarri F, Scolletta S, Tucci E, et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122: 1181-5
8. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation [comment]. Blood 2002; 100: 148-52
9. Wegert W, Graff J, Kaiser D, Breddin HK, Klinkhardt U, Harder S. Effects of antiplatelet agents on platelet-induced thrombin generation. Int J Clin Pharmacol Ther 2002; 40: 135-41
10. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-51
11. Hemker HC, Giesen P, Al Dieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53
12. Siegemund T, Petros S, Siegemund A, Scholz U, Engelmann L. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003; 90: 781-6
13. Mohri M, Sugimoto E, Sata M, Asano T. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation - a comparison with other anticoagulants. Thromb Haemostasis 1999; 82: 1687-93
14. Boisclair MD, Lane DA, Philippou H, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82: 3350-7
15. Despotis GJ, Joist JH, Hogue CW, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902-8
16. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91
17. Marciniak E. Factor-Xa inactivation by antithrombin. 3. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex. Br J Haematol 1973; 24: 391-400
18. Walsh PN, Biggs R. The role of platelets in intrinsic factor-Xa formation. Br J Haematol 1972; 22: 743-60
19. Lakkis N, Lakiss N, Bobek J, Farmer J. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited. Catheter Cardiovasc Interv 2002; 56: 474-7
20. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'. J Clin Invest 1996; 98: 863-74
21. Barrett JS, Murphy G, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994; 56: 377-88
22. Waters JH, Anthony DG, Gottlieb A, Sprung J. Bleeding in a patient receiving platelet aggregation inhibitors. Anesth Analg 2001; 93: 878-82
23. Despotis GJ, Ikonomakou S, Levine V, et al. Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. Thromb Res 1997; 86: 205-19
24. Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90: 1076-9
25. Levy JH, Cormack JG, Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg 1995; 81: 35-7
26. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997; 95: 614-7
27. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984; 63: 394-8
28. Loubser PG, McCarthy JJ, Attar M. Coronary thrombosis associated with antithrombin-III deficiency. J Cardiothorac Vasc Anesth 1997; 11: 756-9
29. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: S715-20
30. Hiramatsu Y, Gikakis N, Anderson HL, et al. Tirofiban provides 'platelet anesthesia' during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1997; 113: 182-93